Vertical Healthcare Consolidation Raises Patient Prices Across 99% of Unreported Deals

Consolidation has accelerated through hospital purchases of physician practices, insurer acquisitions of specialty pharmacies, and private equity roll-ups. These vertical deals bypass meaningful antitrust review because most sit under the annual reporting threshold, allowing incremental market power that regulators cannot easily track via complaints or news monitoring alone. Data from Yale's Health Care Affordability Lab show patients are steered to higher-priced sites and restricted formularies without measurable gains in care coordination or outcomes.

Observational studies in Health Affairs and JAMA Internal Medicine link such integration to 10-20% price increases for outpatient services and imaging, with no consistent improvement in quality metrics. Private equity involvement adds pressure for short-term margins through cost cutting and site-of-service shifts, patterns seen in prior waves of specialty consolidation. Federal tools remain limited to post-merger consent decrees that arrive years late.

Regulators have signaled priority on healthcare competition yet rely on voluntary reporting for smaller transactions. Without updated thresholds or mandatory disclosure of physician practice deals, cumulative effects will continue to compound patient costs. Next steps require legislative changes to the 1976 Act and expanded agency resources for proactive monitoring of vertical chains.